Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst
Portfolio Pulse from Vandana Singh
Needham initiated coverage on Inari Medical Inc (NARI) with a Buy rating and a price target of $72, citing its leadership in the venous thrombectomy market and potential as an acquisition target. Inari Medical's products, FlowTriever and ClotTriever, target markets with a combined TAM of $5.8 billion. The company was also noted for its robust gross margin, double-digit revenue growth, and recent acquisition of LimFlow SA. Potential acquirers include major medical technology firms like Abbott Laboratories, Becton, Dickinson and Co, Boston Scientific, Medtronic, Philips, Stryker, Teleflex, and Terumo. Inari Medical's shares are considered attractively valued, trading at a premium compared to peers.
January 23, 2024 | 7:56 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Abbott Laboratories is identified by Needham as a potential suitor for acquiring Inari Medical, which may affect investor sentiment regarding Abbott's growth strategy.
While Abbott Laboratories is mentioned as a potential acquirer, there is no definitive action or agreement in place. The impact on Abbott's stock price is likely to be neutral in the short term unless further developments regarding an acquisition occur.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Becton, Dickinson and Co is listed as a potential acquirer of Inari Medical, which could influence perceptions of BDX's expansion in the medical technology sector.
Becton, Dickinson and Co's mention as a potential buyer for Inari Medical may not have an immediate impact on its stock price, as no acquisition has been confirmed. The short-term effect is likely neutral, pending further news.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Boston Scientific Corporation is considered a potential buyer for Inari Medical, which may affect investor outlook on Boston Scientific's strategic acquisitions.
The mention of Boston Scientific as a potential acquirer of Inari Medical could have a neutral impact on its stock price in the short term, as there is no concrete acquisition news.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Medtronic Plc is named as a potential suitor for Inari Medical, potentially impacting Medtronic's market expansion plans.
Medtronic's identification as a potential acquirer of Inari Medical is speculative at this stage, likely resulting in a neutral short-term impact on its stock price without further developments.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Koninklijke Philips N.V. is highlighted as a potential acquirer of Inari Medical, which could influence investor sentiment on Philips' acquisition strategy.
Philips' mention as a potential acquirer of Inari Medical may not immediately affect its stock price, as no acquisition has been confirmed. The short-term impact is expected to be neutral.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Stryker Corp is identified as a potential suitor for Inari Medical, which may impact investor views on Stryker's strategic direction.
Stryker's potential interest in acquiring Inari Medical is speculative and may not have a significant short-term impact on its stock price unless further acquisition news emerges.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Teleflex Inc is considered a potential buyer for Inari Medical, which could affect investor expectations regarding Teleflex's growth through acquisitions.
Teleflex's mention as a potential acquirer of Inari Medical is not accompanied by any definitive action, suggesting a neutral short-term impact on its stock price.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Terumo Corp's OTC listing TRUMF is named as a potential suitor for Inari Medical, which may influence investor sentiment on Terumo's strategic acquisitions.
Terumo Corp's OTC listing TRUMF is mentioned as a potential acquirer of Inari Medical, but without concrete developments, the short-term impact on its stock price is likely neutral.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Terumo Corp's OTC listing TRUMY is highlighted as a potential acquirer of Inari Medical, potentially impacting investor perspectives on Terumo's acquisition strategy.
Terumo Corp's OTC listing TRUMY is considered a potential buyer for Inari Medical. However, in the absence of confirmed acquisition plans, the short-term impact on the stock price is expected to be neutral.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Inari Medical Inc is recognized by Needham as a leader in venous thrombectomy with strong growth prospects and as a potential acquisition target, initiating coverage with a Buy rating and a $72 price target.
The positive coverage by Needham, including a Buy rating and a high price target, suggests strong confidence in Inari Medical's market position and growth potential. The mention of Inari as an acquisition target by major firms could also drive investor interest and potentially increase the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100